ProText Mobility, Inc. (TXTM)
USD 0.0
(-11.11%)
USD 0.0
(-11.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 62.41 Thousand USD | 622.04% |
| 2022 | 8644.00 USD | -87.7% |
| 2021 | 70.3 Thousand USD | -76.73% |
| 2020 | 302.15 Thousand USD | 1.21% |
| 2019 | 298.55 Thousand USD | -70.34% |
| 2018 | 1 Million USD | -33.22% |
| 2017 | 1.5 Million USD | -3.14% |
| 2016 | 1.55 Million USD | 0.0% |
| 2013 | 1.43 Million USD | -1.55% |
| 2012 | 1.45 Million USD | 46.24% |
| 2011 | 995.83 Thousand USD | -14.23% |
| 2010 | 1.16 Million USD | -46.37% |
| 2009 | 2.16 Million USD | 5.8% |
| 2008 | 2.04 Million USD | -25.18% |
| 2007 | 2.73 Million USD | 18.34% |
| 2006 | 2.31 Million USD | 391.02% |
| 2005 | 470.69 Thousand USD | 673.94% |
| 2004 | 60.81 Thousand USD | 124.35% |
| 2003 | -249.73 Thousand USD | -147.54% |
| 2002 | 525.31 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 69.67 Thousand USD | 11.64% |
| 2023 Q3 | 51.6 Thousand USD | 4.04% |
| 2023 Q2 | 49.6 Thousand USD | 122.58% |
| 2023 Q1 | 22.28 Thousand USD | 157.81% |
| 2023 Q4 | 62.41 Thousand USD | 20.94% |
| 2023 FY | 62.41 Thousand USD | 622.04% |
| 2022 Q1 | 39.05 Thousand USD | -44.45% |
| 2022 Q4 | 8644.00 USD | 0.0% |
| 2022 FY | 8644.00 USD | -87.7% |
| 2022 Q3 | - USD | 0.0% |
| 2021 Q3 | 70.3 Thousand USD | -8.96% |
| 2021 FY | 70.3 Thousand USD | -76.73% |
| 2021 Q4 | 70.3 Thousand USD | 0.0% |
| 2021 Q2 | 77.22 Thousand USD | -67.15% |
| 2021 Q1 | 235.05 Thousand USD | 0.0% |
| 2020 FY | 302.15 Thousand USD | 1.21% |
| 2019 FY | 298.55 Thousand USD | -70.34% |
| 2018 FY | 1 Million USD | -33.22% |
| 2017 FY | 1.5 Million USD | -3.14% |
| 2016 FY | 1.55 Million USD | 0.0% |
| 2014 Q3 | 1.41 Million USD | 1.01% |
| 2014 Q1 | 1.26 Million USD | -11.61% |
| 2014 Q2 | 1.4 Million USD | 10.89% |
| 2013 Q3 | 1.41 Million USD | 2.42% |
| 2013 FY | 1.43 Million USD | -1.55% |
| 2013 Q1 | 1.43 Million USD | -1.51% |
| 2013 Q4 | 1.43 Million USD | 1.33% |
| 2013 Q2 | 1.38 Million USD | -3.68% |
| 2012 FY | 1.45 Million USD | 46.24% |
| 2012 Q4 | 1.45 Million USD | 7.14% |
| 2012 Q3 | 1.35 Million USD | 9.01% |
| 2012 Q2 | 1.24 Million USD | 12.79% |
| 2012 Q1 | 1.1 Million USD | 11.02% |
| 2011 FY | 995.83 Thousand USD | -14.23% |
| 2011 Q4 | 995.83 Thousand USD | 18.91% |
| 2011 Q3 | 837.49 Thousand USD | 8.52% |
| 2011 Q2 | 771.76 Thousand USD | 7.98% |
| 2011 Q1 | 714.73 Thousand USD | -38.44% |
| 2010 FY | 1.16 Million USD | -46.37% |
| 2010 Q1 | 2.25 Million USD | 4.1% |
| 2010 Q2 | 1.72 Million USD | -23.66% |
| 2010 Q3 | 1.59 Million USD | -7.06% |
| 2010 Q4 | 1.16 Million USD | -27.39% |
| 2009 Q3 | 984.7 Thousand USD | -67.07% |
| 2009 FY | 2.16 Million USD | 5.8% |
| 2009 Q4 | 2.16 Million USD | 119.86% |
| 2009 Q2 | 2.98 Million USD | 16.45% |
| 2009 Q1 | 2.56 Million USD | 25.48% |
| 2008 Q4 | 2.04 Million USD | 21.73% |
| 2008 Q2 | 1.54 Million USD | 66.81% |
| 2008 Q1 | 926.82 Thousand USD | -66.11% |
| 2008 FY | 2.04 Million USD | -25.18% |
| 2008 Q3 | 1.68 Million USD | 8.73% |
| 2007 Q2 | 2.49 Million USD | 13.21% |
| 2007 Q1 | 2.2 Million USD | -4.64% |
| 2007 FY | 2.73 Million USD | 18.34% |
| 2007 Q4 | 2.73 Million USD | -0.26% |
| 2007 Q3 | 2.74 Million USD | 9.91% |
| 2006 Q3 | 2.65 Million USD | 129.52% |
| 2006 FY | 2.31 Million USD | 391.02% |
| 2006 Q2 | 1.15 Million USD | 1.8% |
| 2006 Q1 | 1.13 Million USD | 141.21% |
| 2006 Q4 | 2.31 Million USD | -12.87% |
| 2005 Q3 | 110.27 Thousand USD | 146.62% |
| 2005 Q1 | 55.54 Thousand USD | -8.68% |
| 2005 FY | 470.69 Thousand USD | 673.94% |
| 2005 Q4 | 470.69 Thousand USD | 326.83% |
| 2005 Q2 | -236.56 Thousand USD | -525.91% |
| 2004 Q4 | 60.81 Thousand USD | 206.66% |
| 2004 Q2 | -47.19 Thousand USD | 63.06% |
| 2004 Q1 | -127.76 Thousand USD | 48.84% |
| 2004 FY | 60.81 Thousand USD | 124.35% |
| 2004 Q3 | -57.01 Thousand USD | -20.81% |
| 2003 FY | -249.73 Thousand USD | -147.54% |
| 2003 Q2 | 430.11 Thousand USD | -1.06% |
| 2003 Q4 | -249.73 Thousand USD | -980.13% |
| 2003 Q3 | 28.37 Thousand USD | -93.4% |
| 2003 Q1 | 434.7 Thousand USD | 0.0% |
| 2002 FY | 525.31 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 4864.351% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 98.895% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.854% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 125.003% |
| Rebus Holdings, Inc. | 305 Thousand USD | 79.537% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 100.99% |
| Qrons Inc. | 351.42 Thousand USD | 82.24% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 89.972% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.856% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 405.826% |
| Skye Bioscience, Inc. | -5.72 Million USD | 101.091% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 99.604% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 98.484% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 84.469% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.172% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 97.216% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 93.269% |
| Mesoblast Limited | 55.85 Million USD | 99.888% |
| Marizyme, Inc. | 18.56 Million USD | 99.664% |
| Genus plc | 190.6 Million USD | 99.967% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 97.209% |
| Pharming Group N.V. | 109.8 Million USD | 99.943% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 92.745% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 94.858% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 90.822% |
| ContraFect Corporation | -6.02 Million USD | 101.036% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 53.644% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 94.598% |
| IMV Inc. | 7.67 Million USD | 99.186% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 98.866% |
| MultiCell Technologies, Inc. | 90.04 USD | -69216.97% |
| ONE Bio Corp. | 9.04 Million USD | 99.31% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 108.503% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 99.518% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 95.438% |
| Q BioMed Inc. | 4.06 Million USD | 98.463% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.796% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 93.806% |
| Biomind Labs Inc. | 711.4 Thousand USD | 91.227% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.897% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 96.878% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 99.513% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 82.649% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 55.357% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -214.154% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 97.166% |
| GB Sciences, Inc. | 1.74 Million USD | 96.428% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 133.959% |
| HST Global, Inc. | 96.79 Thousand USD | 35.519% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 69.734% |
| Halberd Corporation | 144.72 Thousand USD | 56.874% |
| Enzolytics Inc. | 981.65 Thousand USD | 93.642% |
| Agentix Corp. | 37.63 Thousand USD | -65.855% |
| Resverlogix Corp. | 6.45 Million USD | 99.033% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 109.273% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.003% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.133% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 99.117% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 97.696% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 100.706% |
| AVAX Technologies, Inc. | -5.9 Million USD | 101.057% |
| Zenith Capital Corp. | 10.06 Thousand USD | -520.161% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.006% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 68.861% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 97.384% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 62.061% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 440.72% |
| Kadimastem Ltd | -253.1 Thousand USD | 124.659% |
| Helix BioMedix, Inc. | -2.57 Million USD | 102.428% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 99.692% |
| BioStem Technologies, Inc. | 4.47 Million USD | 98.604% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 68.988% |
| LadRx Corporation | -2.03 Million USD | 103.065% |
| Cell Source, Inc. | 9.23 Million USD | 99.324% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 90.174% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 90.174% |
| NovAccess Global Inc. | 2.17 Million USD | 97.135% |
| Affymax, Inc. | -5.59 Million USD | 101.115% |
| Itoco Inc. | 228.3 Thousand USD | 72.662% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 54.104% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 98.741% |
| Mobile Lads Corp. | 484.23 Thousand USD | 87.111% |
| CytoDyn Inc. | 20.26 Million USD | 99.692% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 9746.522% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 773.4% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 99.19% |
| SYBLEU INC | 473.71 Thousand USD | 86.825% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 98.6% |
| International Stem Cell Corporation | 2.59 Million USD | 97.59% |
| Bioxytran, Inc. | 1.89 Million USD | 96.713% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 97.138% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 98.182% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 99.27% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 91.922% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 104.993% |
| Neutra Corp. | 52.18 Thousand USD | -19.595% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 102.508% |
| PureTech Health plc | -167.19 Million USD | 100.037% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 125.484% |
| IXICO plc | -4.44 Million USD | 101.404% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 99.528% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.886% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Cellectis S.A. | -43.81 Million USD | 100.142% |